Skip to content

PERsonalized SPeCh Therapy for actIVE conversation

PERsonalized SPeCh Therapy for actIVE conversation - PERSPECTIVE

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON48476
Enrollment
215
Registered
2019-01-23
Start date
2019-03-01
Completion date
Unknown
Last updated
2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's disease

Interventions

The patients will be randomly allocated to either the experimental group or the control group (1:1 ratio). The experimental group will receive speech therapy using tele-rehabilitation for 8 weeks wh

Sponsors

Radboud Universitair Medisch Centrum
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - problems in intelligibility affecting daily communication - a desire for improvement - willing and able to receive online treatment (PC or tablet with webcam and access to internet) - 18 years or older

Exclusion criteria

Exclusion criteria: - recent (

Design outcomes

Primary

MeasureTime frame
The primary outcome measure is the quality of life, measured in the total score on the PDQ-39.

Secondary

MeasureTime frame
The secondary outcomes will include: - speech and voice quality (as assessed objectively with the Radboud Dysarthria Assessment and the Acoustic Voice Quality Index, and subjectively with the Voice Handicap Index) - subjective severity of voice and speech complaints (Radboud Oral Motor inventory for Parkinson's disease) - subjective severity of voice and speech complaints by caregiver (adapted Radboud Oral Motor inventory for Parkinson's disease) - intelligibility (Dutch intelligibility test) - caregiver burden (Zarit caregiver Burden Interview Short Form) - mood and anxiety (Hospital Anxiety and Depression Scale) - generic quality of life (EuroQol-5d) - swallowing rate (ml/s) - treatment report that speech therapists will fill out after treatment has been completed

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)